Ipilimumab for metastatic melanoma Journal Article
| Authors: | Ozao-Choy, J.; Carvajal, R. D.; Hamid, O. |
| Article Title: | Ipilimumab for metastatic melanoma |
| Abstract: | Malignant melanoma is currently the fifth most common cancer in American men and the seventh most common in American women. Despite the advances made for early disease, the prognosis for metastatic melanoma is dismal, with an overall 5-year mortality rate of 90%. It is estimated that 8,000 Americans will die of melanoma in 2012. Recent advances in the understanding of the complex cellular interactions regulating cancer immunity have led to new strategies in the development of cancer immunotherapy. The discovery of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of immune activity, has led to the development of a monoclonal antibody, ipilimumab, that can abrogate immune suppression. Ipilimumab is the first immunotherapy approved by the FDA for patients with advanced melanoma based on the overall survival benefit in a phase III setting. It represents a paradigm shift in melanoma management with its success promoting the evaluation of monoclonal antibodies targeted against a number of other regulatory checkpoints in patients with advanced melanoma. Copyright © 2012 Prous Science, S.A.U. or its licensors. All rights reserved. |
| Keywords: | cancer survival; treatment response; leukemia; unclassified drug; overall survival; prednisone; drug tolerability; paresthesia; hepatitis; bevacizumab; placebo; advanced cancer; cancer combination chemotherapy; cancer risk; diarrhea; drug dose comparison; drug efficacy; drug withdrawal; systemic therapy; alpha interferon; adjuvant therapy; cancer adjuvant therapy; disease free survival; rituximab; drug megadose; antineoplastic agent; tumor associated leukocyte; alpha2b interferon; dacarbazine; glycoprotein gp 100; interleukin 2; ipilimumab; cancer immunotherapy; melanoma; drug eruption; multiple cycle treatment; granulocyte macrophage colony stimulating factor; steroid; antineoplastic activity; kidney carcinoma; abdominal pain; drug dose escalation; prostate cancer; gastrointestinal toxicity; b cell lymphoma; colonoscopy; vaccination; nausea and vomiting; colitis; immunomodulation; colon perforation; weakness; sensory dysfunction; hyperthyroidism; hypothyroidism; kidney cancer; corticosteroid; cytotoxic t lymphocyte antigen 4; immunosuppressive treatment; autoimmune disease; adoptive immunotherapy; antigen presenting cell; topical treatment; peripheral blood mononuclear cell; abdominal radiography; stevens johnson syndrome; antidiarrheal agent; metastatic melanoma; adrenal insufficiency; randomized controlled trial (topic); hematochezia; phase 2 clinical trial (topic); budesonide; phase 1 clinical trial (topic); hypopituitarism; hypertransaminasemia; corticosteroid therapy; multicenter study (topic); anti-ctla-4; vemurafenib; acid phosphatase prostate isoenzyme; upper abdominal pain; cytotoxic t-lymphocyte-associated antigen 4; incb 024360; nivolumab; typhoid paratyphoid vaccine |
| Journal Title: | Drugs of Today |
| Volume: | 48 |
| Issue: | 6 |
| ISSN: | 1699-3993 |
| Publisher: | Prous Science |
| Date Published: | 2012-06-01 |
| Start Page: | 381 |
| End Page: | 393 |
| Language: | English |
| DOI: | 10.1358/dot.2012.48.6.1811777 |
| PROVIDER: | scopus |
| PUBMED: | 22745924 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 4 September 2012" - "CODEN: MDACA" - "Source: Scopus" |
